Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AA Phase IIA Open-Label, Randomized, PK Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in MM Patients Undergoing Autologous Transplantation

Trial Profile

AA Phase IIA Open-Label, Randomized, PK Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in MM Patients Undergoing Autologous Transplantation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics; Registrational
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2016 According to a Spectrum Pharmaceuticals media release, EVOMELA was approved by the FDA based on its bioequivalence to the standard melphalan formulation (Alkeran) via the 505(b)(2) regulatory pathway.
    • 15 Mar 2016 According to a Ligand Pharmaceuticals media release, based on the results of this trial, company has received approval from the U.S. Food and Drug Administration (FDA) of melphalan (EVOMELA) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma, and 2) for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
    • 23 Oct 2015 According to a Spectrum Pharmaceuticals media release, the company has received a Complete Response Letter from the U.S. FDA for propylene glycol-free melphalan formulation [Evomela]. The FDA has not identified any clinical deficiency in Spectrum's NDA submission and the company plans to meet with the FDA and seek clarification on the Complete Response Letter.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top